Testimony of Anna Abram, FDA Deputy Commissioner for Policy, Planning, Legislation, and Analysis
Before the House Committee on Energy and Commerce, Subcommittee on Health
June 6, 2018
Chairman Burgess, Ranking Member Green, and members of the committee, thank you for the opportunity to appear today to discuss reauthorization of the Pandemic and All-Hazards Preparedness Act (PAHPA).
This most recent Ebola outbreak underscores the need to continue to optimize our preparedness and response capabilities. PAHPA, which was enacted in 2006 and reauthorized in 2013, is a key piece of legislation that—along with other significant legislative achievements such as the Project BioShield Act of 2004, the Public Readiness and Emergency Preparedness (PREP) Act (2005), and the 21st Century Cures Act (Cures Act) enacted in 2016—has served to significantly strengthen our Nation's preparedness for, and capabilities to respond to, public health emergencies involving chemical, biological, radiological, and nuclear (CBRN) threats, as well as emerging infectious disease threats, such as Zika virus, Ebola virus, and pandemic influenza.
The Pandemic and All-Hazards Preparedness Reauthorization Act of 2013 (PAHPRA), in particular, recognized the key role FDA plays in emergency preparedness and response, and codified and built on FDA’s ongoing efforts to augment review processes and advance regulatory science to enable better response to public health emergencies. The provisions in PAHPRA—as well as in the other key pieces of legislation I mentioned—have provided FDA with essential tools that continue to support us in our mission to protect and promote public health.
FDA’s Public Health Emergency Preparedness and Response Mission
FDA plays a critical role in facilitating preparedness for and response to not just CBRN threats, but emerging infectious disease threats, which can and often do emerge with little to no warning as was the case with the anthrax attacks of 2001, the 2009 H1N1 influenza pandemic, the 2014 Ebola outbreak in West Africa, the emergence of Zika virus in 2016, and the recent Ebola outbreak in DRC.
FDA’s role in facilitating preparedness for, and response to, CBRN and emerging infectious disease threats focuses largely on facilitating the development and availability of medical countermeasures—such as vaccines, therapeutics, and diagnostic tests—to respond to these threats. FDA works closely with its HHS and other U.S. government partners through the Public Health Emergency Medical Countermeasures Enterprise (PHEMCE), as well as with regulated industry and non-governmental organizations (NGOs), to sustain and optimize the medical countermeasure framework necessary to effectively respond to public health emergencies. FDA is also committed to continuing to work closely with the Department of Defense (DoD) to facilitate the development and availability of medical countermeasures to support the unique needs of our Nation’s military personnel.
FDA’s Medical Countermeasures Initiative (MCMi)—established in 2010—brought enhanced resources to FDA that enabled FDA to hire additional expert staff and to become more deeply and thoroughly engaged in medical countermeasure activities. This program continues to be key to providing clear regulatory pathways for medical countermeasures, advancing medical countermeasure regulatory science to support regulatory decision making, and advancing important policies and mechanisms to facilitate the timely development and availability of medical countermeasures. FDA’s goal is to be efficient and to use the most up-to-date science in its regulation of safe and effective medical products, and that includes medical countermeasures.
FDA’s operations within its medical countermeasures mission cover a broad range of activities vital to facilitating the development of, and access to, safe and effective medical countermeasures, including:
- Reviewing marketing applications for medical countermeasures and approving those that meet standards for safety and efficacy;
- Providing regulatory advice, guidance and technical assistance to sponsors developing medical countermeasures, as well as to U.S. government partners, international regulators, and international organizations such as the World Health Organization;
- Supporting efforts to establish and sustain an adequate supply of medical countermeasures, including averting supply disruptions when feasible and, in certain situations, allowing products to be used beyond their labeled expiration dates when supported by appropriate scientific evaluation;
- Enabling access to medical countermeasures that are not yet approved—when necessary—through an appropriate mechanism, including through FDA’s Emergency Use Authorization (EUA) authority;
- Proactively identifying and resolving regulatory challenges associated with medical countermeasure development and ensuring that FDA regulations and policies adequately support timely medical countermeasure development and enable preparedness and response activities and capabilities;
- Fostering the professional development of FDA scientists to ensure that FDA personnel maintain the skills and abilities to support the medical countermeasure mission; and
- Supporting regulatory science to create the tools, standards, and approaches necessary to develop and assess the safety, efficacy, quality, and performance of medical countermeasures.
Fostering Innovation in Medical Countermeasure Development
At FDA, we fully appreciate that the development of medical countermeasures can present complex and unique challenges. For example, it is not ethical to conduct human studies for many of the high-priority threat agents. In these situations, the Animal Rule, which enables animal efficacy studies to substitute for efficacy trials in humans if the results can reasonably be extrapolated to the expected human use, can be used to facilitate the development and availability of medical countermeasures. PAHPRA recognized the importance of the Animal Rule; and in 2015, FDA finalized guidance for product development under the Animal Rule, incorporating the learnings of considerable product development experience and providing scientific and regulatory expectations for animal data intended to support medical countermeasure approval.
To date, 13 medical countermeasures have been approved under the Animal Rule, including inhalational anthrax therapeutics, a botulism antitoxin, antibiotics for the treatment and prophylaxis of plague, and treatments for acute radiation syndrome. These approvals underscore the critical role the Animal Rule and animal studies can play in advancing medical countermeasures for some of the most challenging threats. Of note, through the use of regulatory science, FDA was able to approve the inhalational anthrax therapeutics and the botulism antitoxin for use in children as well as adults, despite the fact that ethical concerns precluded studying pediatric patients in clinical trials.
However, there are threats for which we continue to seek to strengthen our regulatory science because of current regulatory gaps, such as due to the lack of animal models to support medical countermeasure development or sufficient biomarkers to enable the extrapolation of data generated in animal models to humans for these threats. Without such tools, it is difficult to generate the data necessary to support regulatory decision making. Given the urgency inherent in our medical countermeasure work, addressing these regulatory science gaps remains a high priority for the Agency.
To that end, FDA has established a broad and robust portfolio of cutting-edge research under the MCMi Regulatory Science Program to help develop these tools and promote innovation in the development of medical countermeasures. A few examples of projects include: supporting the development of organs-on-chips models to assess radiation damage in lung, gut, and bone marrow, and then using these models to test candidate medical countermeasures; collaborating to establish a publicly available genomic sequence reference database for use by developers seeking to validate candidate multiplex in vitro diagnostic tests that could be used to diagnose multiple pathogens simultaneously; developing reference materials for developers to use to validate nucleic acid-based and serological diagnostic tests for Zika virus; supporting a project to identify and correlate biomarkers of host response to Ebola virus infection in animal models and humans to support medical countermeasure development; developing methods for obtaining safety and limited efficacy data from patients who receive medical countermeasures during public health emergencies; and establishing the Animal Model Qualification Program designed to support medical countermeasure development by promoting the development of animal models for use across multiple product applications, thereby minimizing duplication of effort and resources.
PAHPRA also provided authorities to ensure that FDA personnel are well-trained in how to review medical countermeasure applications for approval. Under these authorities, FDA has established a professional development program, including speakers’ series and academic certifications, to ensure that FDA scientists are working through the regulatory challenges posed by new areas of science and technology as they relate to medical countermeasure development. FDA also has spent considerable energy and resources establishing an efficient approach to conduct and support training within the agency.
More recently, the 21st Century Cures Act (the Cures Act) included several provisions that are intended to advance innovation in medical product development more generally, but will also help to facilitate the development of medical countermeasures including the provisions to encourage novel trial designs, and to develop new antimicrobial drug products, in addition to the medical countermeasure specific provisions included in that law.
Through the Cures Act, Congress provided a new priority review voucher (PRV) program to help incentivize the development of material threat medical countermeasures. Under this program, FDA will award a PRV upon approval of a material threat medical countermeasure application provided that certain criteria are met. The PRV may in turn be used by the sponsor who receives it, or sold to another sponsor, who may then use it to obtain priority review for a product application that would otherwise not receive that benefit, enabling a developer to potentially bring a product to market sooner than otherwise possible—something that may be of great value to product developers. FDA issued draft guidance in January 2018 that explains how the Agency is implementing the material threat medical countermeasure PRV program. FDA is considering comments received on the draft guidance prior to issuing a final guidance document.
There are tremendous opportunities to continue to further the development of groundbreaking, innovative medical countermeasures, and the Agency intends to fully seize and build upon these opportunities. Toward that goal, in July 2017 FDA launched a comprehensive Innovation Initiative aimed at making sure its regulatory processes are efficient and use the most up-to-date science so that safe and effective new technologies, including medical countermeasures, can reach patients in a timely fashion.
Facilitating Access to Safe and Effective Medical Countermeasures
Enabling access to medical countermeasures when they are needed is a high priority for FDA. Amended and new authorities provided by Congress have enabled the Agency to further prepare for, and better respond to, emerging public health threats. For example, PAHPRA amended FDA’s EUA authority to provide additional flexibility for issuing EUAs. These additional flexibilities have enabled FDA to better support responses to emerging health threats by issuing nearly 40 EUAs to enable the emergency use of in-vitro diagnostic devices for H7N9 Influenza virus, Enterovirus D68 (EV-D68), Middle East Respiratory Syndrome Coronavirus (MERS-CoV), Ebola virus, and Zika virus. FDA also issued an EUA to enable the emergency use of an auto- injector medical countermeasure to maintain preparedness for chemical threats, which has been critical for supporting both military personnel and first responder preparedness goals related to an emergency involving nerve agents. The authority for prepositioning medical countermeasures provided in PAHPRA also proved useful to allow the manufacturer to ship, and the U.S. government stakeholders to receive, certain strengths of the unapproved auto-injectors that were not yet authorized for use under that EUA.
PAHPRA also provided FDA with several new streamlined authorities to facilitate the emergency use of approved medical countermeasures without the need for issuing an EUA. For example, PAHPRA provided FDA with the authority to issue emergency dispensing orders (including mass dispensing at a point of dispensing) for approved medical countermeasures during an actual CBRN emergency without requiring an individual prescription for each recipient of the medical countermeasure, if permitted by state law or in accordance with an emergency dispensing order issued by FDA. FDA has used this authority to issue emergency dispensing orders to permit emergency dispensing of doxycycline and ciprofloxacin for post-exposure prophylaxis of inhalational anthrax, to ensure government stakeholders can rapidly provide these therapies in the event of an anthrax attack.1
Additionally, PAHPRA specified that the HHS Secretary may, acting through an appropriate HHS official, create and issue emergency use instructions (EUI) about medical countermeasures to inform health care professionals and patients/recipients about the medical countermeasures’ approved, licensed, or cleared conditions of use before or during an emergency. The EUI authority—which the HHS Secretary delegated to the Director of the Centers for Disease Control and Prevention (CDC) in 2013—allows CDC to provide streamlined information about the use of eligible, approved medical countermeasures needed during public health emergencies. To facilitate creation of EUI, FDA and CDC entered into a Memorandum of Understanding, and when feasible, FDA and CDC coordinate the issuance of EUI (as well as emergency dispensing orders). For example, FDA and CDC have issued “emergency preparedness packages,” including EUI and emergency dispensing orders, for doxycycline and ciprofloxacin for post-exposure prophylaxis during an anthrax emergency, should such an event occur.
Another new FDA authority created by PAHPRA is the explicit ability to extend expiration dating of eligible FDA-approved medical countermeasures stockpiled for use in CBRN emergencies, if the extension is supported by an appropriate scientific evaluation. This authority streamlines FDA’s ability to authorize expiration dating extensions without the need to issue an EUA, which will enable faster response, and has been crucial to FDA’s ability to support preparedness efforts. For example, when production stopped after quality issues were identified in the manufacturing process of auto-injectors used for the treatment of nerve agent and insecticide poisoning, FDA used this authority to help prevent shortages of auto-injector products to help ensure that the Nation’s military personnel and first responders continue to have ready access to these products. FDA also used this authority to extend the expiration date of certain lots of doxycycline capsules held in strategic stockpiles by CDC, state and local public health agencies, and other emergency response stakeholders and issued draft guidance to provide recommendations to government stakeholders on testing that can be conducted to support future extensions, in order to help sustain preparedness levels.
The Cures Act also amended the EUA and related emergency use authorities to clarify their applicability to animal drugs. FDA encourages anyone interested in utilizing these authorities to contact FDA to discuss how to proceed.
More recently, Congress passed H.R. 4374, legislation that amends FDA’s EUA authority to enable FDA to issue EUAs for medical products to reduce deaths and mitigate injuries from agents that may cause imminently life-threatening and specific risks to United States military forces. Prior to the passage of this legislation, the EUA authority was only applicable to medical products to address CBRN threats. In addition, the legislation contains provisions codifying enhanced collaboration between FDA and DoD, in order to facilitate the development of medical products and countermeasures for military personnel. Senior leadership at the Agency is working closely with DoD to quickly implement these new and amended authorities, and we look forward to keeping Congress informed of our progress in these critical areas.
FDA looks forward to working with Congress and continuing to improve the Agency’s ability to effectively support public health preparedness and response efforts.
At FDA, we have made it a priority to proactively work with our private sector and government partners to help facilitate the translation of discoveries in science and technology into safe and effective medical countermeasures. FDA takes seriously its responsibility to help drive and foster innovation as part of advancing public health and strengthening our national security. Active FDA involvement is essential to encouraging industry engagement in medical countermeasure development. FDA remains deeply committed to working closely with its partners and continuing to use the authorities Congress provides to the fullest extent to help facilitate and accelerate the development and availability of safe and effective medical countermeasures. We believe that partnership and innovation will continue to be key elements to success in our medical countermeasure endeavors, and we are taking steps to further empower FDA’s scientific and clinical experts to help support and drive the innovation necessary to protect the nation from the threats we may face.
FDA appreciates Congress’s support in continually optimizing its authorities—and providing resources—to enable FDA to achieve its public health emergency preparedness and response mission. FDA stands ready to work with Congress and stakeholders to enable us to better achieve this critical work.
Thank you for inviting FDA to testify today. I look forward to answering any questions you may have about FDA’s medical countermeasure work.
1 The term “stakeholder(s)" means the public agency or its delegate that has legal responsibility and authority for responding to an incident, based on political or geographical boundary lines (e.g., city, county, tribal, State, or Federal), or functional (e.g., law enforcement or public health range) or sphere of authority to prescribe, administer, deliver, distribute, or dispense oral doxycycline products in an emergency situation.